1-Azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-Azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid
• 化学式: C27H32N2O6
• 分子量: 480.6
• InChiKey: RXZMMZZRUPYENV-DZSUWJOWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  7

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：由于没有发表的使用索利那新期间母乳喂养的经验，且其平均半衰期长达55小时，可能更倾向于选择其他药物，特别是在哺乳新生儿或早产儿时。长期使用索利那新可能会减少乳汁产量或乳汁排放。长期使用期间，观察婴儿是否有乳汁产量减少的迹象（例如，不饱足，体重增长不良）和抗胆碱能症状（例如，便秘，尿潴留，尿路感染，口干）。 ◉ 对哺乳婴儿的影响：截至修订日期，未找到相关已发表的资料。 ◉ 对泌乳和母乳的影响：抗胆碱能药物可以在动物中抑制泌乳，可能是通过抑制生长激素和催产素的分泌。抗胆碱能药物也可以减少非哺乳妇女的血清催乳素水平。对于已经建立泌乳的母亲，催乳素水平可能不会影响她的哺乳能力。

◉ Summary of Use during Lactation:Because there is no published experience with solifenacin during breastfeeding and it has a long half-life averaging 55 hours, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Long-term use of solifenacin might reduce milk production or milk letdown. During long-term use, observe the infant for signs of decreased milk production (e.g., insatiety, poor weight gain) and for anticholinergic symptoms (e.g., constipation, urinary retention, UTI, dry mouth). ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Anticholinergics can inhibit lactation in animals, apparently by inhibiting growth hormone and oxytocin secretion. Anticholinergic drugs can also reduce serum prolactin in nonnursing women. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

来源:Drugs and Lactation Database (LactMed)

文献信息

• [EN] N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS<br/>[FR] CARBOXAMIDES N-PYRAZOLYL EN TANT QU'INHIBITEURS DU CANAL CRAC
  申请人：GLAXO GROUP LTD

  公开号：WO2010122089A1

  公开（公告）日：2010-10-28

  The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

  本发明涉及酰胺化合物，其制备方法，含有这些化合物的药物组合物，以及它们在治疗过敏性疾病、炎症性疾病和免疫系统疾病等疾病、状况或障碍中的应用。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2012035055A1

  公开（公告）日：2012-03-22

  The invention is directed to certain novel compounds. Specifically, the invention directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.

  这项发明涉及某些新颖的化合物。具体地，该发明涉及公式（I）的化合物及其盐。该发明的化合物是激酶活性抑制剂，特别是Itk活性的抑制剂。
• [EN] SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：CALITOR SCIENCES LLC

  公开号：WO2015148868A1

  公开（公告）日：2015-10-01

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新颖的杂环芳基化合物，其药用盐和制剂，在预防、治疗或减轻蛋白介导的疾病的严重程度方面具有用处。该发明还提供了包括这些化合物的药用组合物以及使用这些组合物治疗蛋白激酶介导的疾病的方法。
• [EN] DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE 2-[2-(BENZO- OU PYRIDO-)THIAZOLYLAMINO]-6- AMINOPYRIDINE, UTILES DANS LE TRAITEMENT DE MALADIES RESPIRATOIRES, ALLERGIQUES OU INFLAMMATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2011110575A1

  公开（公告）日：2011-09-15

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.

  本发明涉及某些新型化合物。具体而言，本发明涉及通式（I）的化合物及其盐。本发明的化合物是激酶活性的抑制剂，特别是Itk活性的抑制剂。
• [EN] PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS COMME INHIBITEURS DE LTK
  申请人：GLAXO GROUP LTD

  公开号：WO2010106016A1

  公开（公告）日：2010-09-23

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular ltk activity.

  本发明涉及某些新颖化合物。具体而言，本发明涉及以下公式（I）的化合物及其盐类。发明的化合物是激酶活性的抑制剂，特别是ltk活性的抑制剂。